GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

Elevance Health Inc

ELV vs. GDRX: Which Stock Is the Better Value Option?

ELV vs. GDRX: Which Stock Should Value Investors Buy Now?

The stock is down more than 85% from its 52-week high.

Is GoodRx's Drop a Bear Market Opportunity?

The company's large subscriber base is impressive.

Is GoodRx a Growth Stock Worth Considering?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it will release its second quarter 2022 financial results after U.S. markets close on Monday, August 8, 2022. GoodRx management will hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. Prior to the call, GoodRx will issue a press release containing

GoodRx Announces Date for Second Quarter 2022 Earnings Release and Conference Call

Its business model is being put to the test, and it just might pass.

Is This Distressed Growth Stock About to Make a Comeback?

ANGI Homeservices

Infinera

Kosmos Energy

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 5 Well-Known Buy-Rated Stocks Under $10 With Solid Upside Potential

LOS ANGELES , June 1, 2022 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) investors concerning the Company's possible violations of the federal securities laws.   If you suffered a loss on your GoodRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/goodrx-holdings-inc-1/.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

BENSALEM, Pa. , June 1, 2022 /PRNewswire/ -- Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

LOS ANGELES , June 1, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Continues Its Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX). The investigation concerns whether GoodRx has violated the federal securities laws and/or engaged in other unlawful business practices. GoodRx's core business is a healthcare technology platform that provides consumers with a prescription discount card to get discounted pricing on prescription drugs. On February 28, 2022, afte

Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of GoodRx Holdings, Inc. (GDRX) Investors

Airbnb

These stocks are down, but investors shouldn't count them out.

2 Growth Stocks That Are Likely to Bounce Back This Year

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced a strategic relationship with RxVantage that will enable healthcare providers to connect with manufacturers on the GoodRx platform. Over 700,000 prescribers have used GoodRx since June 2021, and GoodRx expects the new integration from this strategic relationship will enable them to easily connect with pharma representatives to ask questions about new therapies, i

GoodRx and RxVantage Announce Strategic Relationship to Streamline Communications Between Providers and Manufacturers

Palantir Technologies

Investors shouldn't count these stocks out just yet.

2 Growth Stocks at All-Time Lows That Could Be the Ultimate Contrarian Buys

NEW YORK--(BUSINESS WIRE)-- #GDRX--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) on behalf of GoodRx stockholders. Our investigation concerns whether GoodRx has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 9, 2022, after the market closed, GoodRx announced its first

GOODRX ALERT: Bragar Eagel & Squire, P.C. Is Investigating GoodRx, Inc. on Behalf of GoodRx Stockholders and Encourages Investors to Contact the Firm

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of GoodRx Holdings, Inc. (GDRX) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your GoodRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities l

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) investors concerning the Company's possible violations of federal securities laws. On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance. In its shareholder letter, the Company stated that “a grocery chain had taken actions that impacted acceptance

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 9, 2022, after the market closed, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance. In its shareholder letter, the Com

The Law Offices of Frank R. Cruz Announces Investigation of GoodRx Holdings, Inc. (GDRX) on Behalf of Investors

A grocery store chain is making changes that could cost GoodRx $30 million next quarter.

Why GoodRx Stock Got Hammered Today

GoodRx Holdings Inc (NASDAQ: GDRX) shares fell after it expects FY22 revenue to take a hit due to recent actions by one grocery store chain that represents a sizable chunk of its grocery prescription business. The company disclosed that it is unlikely to achieve its full-year guidance.

GoodRx Shares Tumble As FY22 Guidance Hit By Grocery Chain Prescription Dispute

GoodRx (GDRX) stock is slipping on Tuesday despite the healthcare company beating out estimates for the first quarter of 2022. The post Why Is GoodRx (GDRX) Stock Down Today?

Why Is GoodRx (GDRX) Stock Down Today?

Showing how one relationship can reverberate across a marketplace and a sector, GoodRx — and possibly competitors — got smacked in Q1 by a dispute by an unnamed grocery chain representing a meaningful chunk of the grocery prescription business. Noting that first quarter 2022 performance of prescription related offerings “was largely in line with the […]

GoodRx Q1 2022 Performance Marred by Mystery Grocery Chain Prescription Beef

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 25% and 1.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

GoodRx Holdings, Inc. (GDRX) Beats Q1 Earnings and Revenue Estimates

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Whitney Notaro - Vice President, Investor Relations Doug Hirsch - Co-Founder & Co-Chief Executive Officer Trevor Bezdek - Co-Founder Co-Chief Executive Officer, Karsten Voermann - Chief Financial Officer Conference Call Participants Justin Post - Bank of America John Ransom - Raymond James Mark Mahaney - Evercore George Hill - Deutsche Bank Sean Dodge - RBC Capital Markets Sandy Draper - Guggenheim Charles Rhyee - Cowen Ricky Goldwasser - Morgan Stanley Glen Santangelo - Jefferies Stephanie Davis - SVB Doug Anmuth – JPMorgan Steven Valiquette - Barclays Jonathan Yong - Credit Suisse Stan Berenshteyn - Wells Fargo Operator Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx First Quarter 2022 Earnings Call. At this time -- as a reminder, today's conference call is being recorded.

GoodRx Holdings, Inc. (GDRX) CEO Doug Hirsch on Q1 2022 Results - Earnings Call Transcript

Shares of GoodRx Holdings Inc. sank in after-hours trading Monday after the company, which offers tools that help consumers compare drug prices, exceeded expectations with its March-quarter results but disclosed that it is unlikely to achieve its full-year outlook due to recent actions taken by a grocery chain.

News for GoodRx Holdings Stock (GDRX)